Can we draw a line through the data?PGX-YBG is found multi-fold more immune stimulative than competitors in human cell-lines. Gilles considers it so compelling he might want to go-it-alone in the immune booster market with 40 million dose plant with $100 million net present value.
PGX-YBG/CoQ10 is found superior to industry gold standard in University of Alberta bioavailability study. PGX-YBG may act as a Trojan Horse for the delivery of bioactives/drugs by hijacking macrophages. PGX may allow the creation of faster or slower release formulations and is highly loadable.
PGX-YBG/fibrosis could profoundly change the landscape of fibrosis treatment if preclinical results are replicated according to Dr. Martin Kolb. Results with McMaster were recently sent to prominent industry journal Biomaterials for peer-review. A new mechanism of action for binding to white blood cells is discovered for inflammatory and fibrotic disease.
CZO potentially has the only inhalable yeast beta glucan allowing bioactives/drugs to be delivered to the lungs.
CZO attracts Canadian pharmaceutical icon Ronnie Miller.
At the last AGM Gilles said they have had discussions with potential partners who are pretty impressed and understand bioavailability as a unique selling point for CoQ10.
CZO hires industry leader NATEX for PGX-scale-up to the decision point for mass industrialization of PGX(100L).
CZO completes merger with AEZS. Ronnie Miller says he's "thrilled" and Gilles calls it "exciting". CZO is now on NASDAQ ahead of key events with optimized company to bring "transformational products" to the market.
Ronald W. Miller, Chair of the Company: “With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.” The merger adds key and complementary human resources and capital.
The scale-up of PGX to 50L is said "almost completed" after three trial runs. Health Canada approval could come before year-end for the first commercial PGX product. The 100L scale-up is expected to be commissioned in the next approximately three months and is the decision point for mass industrialization of PGX.
Nov 2022:
"This next phase of scale up will allow us to work with commercial partners in nutraceuticals and pharmaceuticals to formulate, test, and commercialize novel products and formulations, including novel functional foods and beverages, novel drugs and various forms of delivery systems,” said Gilles Gagnon, M.Sc., MBA, President and CEO."